NAMS NEWAMSTERDAM PHARMA COMPANY B.V.

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

NAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

  • 8th Annual Evercore Healthcare Conference in Coral Gables, FL on Tuesday, December 2, 2025. Ian Somaiya, Chief Financial Officer, will participate in a fireside chat at 3:50 p.m. ET on Tuesday, December 2.
  • Citi’s 2025 Global Healthcare Conference in Miami, FL on Wednesday, December 3, 2025. Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will participate in a fireside chat at 3:15 p.m. ET on Wednesday, December 3.
  • Piper Sandler 37th Annual Healthcare Conference in New York, NY on Thursday, December 4, 2025. Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will participate in a fireside chat at 8:00 a.m. ET on Thursday, December 4.



Live webcasts of the fireside chats will be available through the investor relations section of the NewAmsterdam Pharma website at . Following the live webcasts, archived replays will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact

Matthew Philippe

P: 1-917-882-7512

Media Contact

Real Chemistry on behalf of NewAmsterdam

Christian Edgington

P: 1-513-310-6410

Investor Contact

Precision AQ on behalf of NewAmsterdam

Austin Murtagh

P: 1-212-698-8696



EN
25/11/2025

Underlying

NAMSNEWAMSTERDAM PHARMA COMPANY B.V.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEWAMSTERDAM PHARMA COMPANY B.V.

 PRESS RELEASE
Free
NAMS NEWAMSTERDAM PH...

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in...

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December NAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcom...

8h / 6m 1 EN
 PRESS RELEASE
Free
NAMS NEWAMSTERDAM PH...

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rul...

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAARDEN, The Netherlands and MIAMI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Di...

November 7, 2025 1 EN
 PRESS RELEASE
Free
NAMS NEWAMSTERDAM PH...

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarte...

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results – Marketing Authorization Applications for obicetrapib and FDC of obicetrapib plus ezetimibe accepted for review by European Medicines Agency – – BROOKLYN and BROADWAY pooled MACE analysis published in the Journal of the American College of Cardiology, while the BROADWAY pre-specified Alzheimer’s substudy was published in the Journal of Prevention of Alzheimer's Disease – – $756.0 million in cash, cash equivalents and marketable securities at September 30, 2025 – NAARDEN, the Netherlands and MIAMI,...

November 5, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.42
WCC WESCO Internati...
VIAV Viavi Solutions... ... (+44)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

WCC WESCO INTERNATIONAL INC.
VIAV VIAVI SOLUTIONS INC
ROG ROGERS CORPORATION
PBYI PUMA BIOTECHNOLOGY INC.
OMCL OMNICELL INC.
HII HUNTINGTON INGALLS INDUSTRIES INC.
GPRK GEOPARK
FORM FORMFACTOR INC.
CALX CALIX NETWORKS
AME AMETEK INC.
AVNW AVIAT NETWORKS
EFR ENERGY FUELS
CAH CARDINAL HEALTH INC.
CMCO COLUMBUS MCKINNON CORPORATION
ORN ORION GROUP HOLDINGS
CHRW C.H. ROBINSON WORLDWIDE INC.
JBSS JOHN B. SANFILIPPO & SON INC.
LAUR LAUREATE EDUCATION INC. CLASS A
OSW ONESPAWORLD HOLDINGS (A)
FOX FOX CORPORATION CLASS B
AEYE AUDIOEYE INC
REEMF RARE ELEMENT RESOURCES
GCI GANNETT CO. INC.
CMPR CIMPRESS PLC
TT TRANE TECHNOLOGIES PLC
SOPH SOPHIA GENETICS SA
ROIV ROIVANT SCIENCES LTD
MCW MISTER CAR WASH INC
PPTA PERPETUA RESOURCES CORP
CRML CLAL INDUSTRIES & BEVERAGES LTD
FTAI FORTRESS TRANSN & INFRAS INVS LLC
NAMS NEWAMSTERDAM PHARMA COMPANY B.V.
GPCR STRUCTURE THERAPEUTICS
LAES SEALSQ CORP
NB NIOCORP DEVELOPMENTS LTD.
FTK FLOTEK INDUSTRIES INC.
IDR IDAHO STRATEGIC RESOURCES INC
ESEA EUROSEAS LTD
CDTX CIDARA THERAPEUTICS INC.
PRM PERIMETER SOLUTIONS INC
MAZE MAZE THERAPEUTICS INC
FRGE FORGE GLOBAL HLDGS INC
LTBR LIGHTBRIDGE CORP
GSAT GLOBALSTAR INC.
10/31/25 October 31, 2025 1 EN
 PRESS RELEASE
Free
NAMS NEWAMSTERDAM PH...

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Inv...

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November NAARDEN, The Netherlands and MIAMI, Oct. 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional safety and e...

October 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch